Proteus Digital Health said today that the first cancer patients were treated using its digital oncology therapy, which combines oral chemotherapy with an ingestible sensor. Patients with stage 3 and 4 colorectal cancer at the University of Minnesota Health and Fairview Health Services were treated with digital capecitabine. The Redwood City, Calif.-based company plans to use […]
How AI can detect cervical cancer
Researchers have developed a computer algorithm that they say can analyze digital images of a woman’s cervix and accurately identify precancerous changes that require medical attention. This artificial intelligence approach, called automated visual evaluation, has the potential to revolutionize cervical cancer screening, particularly in low-resource settings. Led by investigators from the National Institutes of Health […]
Olympus inks precision cancer imaging and treatment dev deal with USC
Olympus (TYO:7733) said late last week that it inked a co-development partnership with the University of Southern California looking to advance multiscale research into cancer prevention, diagnosis and treatment through the use of precision medicine. The deal is a first for the university and the company, Olympus said, adding that it hopes that the personalized treatments […]
AngioDynamics beats The Street with Q2 results
Shares in AngioDynamics (NSDQ:ANGO) rose today after the medical device maker topped expectations on Wall Street with its second quarter financial results. The Latham, N.Y.-based company posted profits of $2.1 million, or 6¢ per share, on sales of $91.5 million for the 3 months ended Nov. 30, for sales growth of 5.5% compared with the same […]
iCad inks $7m private placement deal
iCad (NSDQ:ICAD) said this week that it landed a $7 million private placement deal with institutional investors. The company will pay interest to the investors on the outstanding principal amount at an annual rate of 5%, according to a report filed with the SEC. The convertible debentures mature on Dec. 21, 2021. Prior to the maturity […]
DermaSensor raises $5.8m for handheld cancer detection device
DermaSensor has raised $5.8 million from 23 investors in an offering that began in November, according to a report filed with the SEC this month. The Florida-based company’s handheld device uses a light-emitting tip to evaluate potentially cancerous lesions on the surface of a patient’s skin. Using precision optics, the device can detect cellular pathological […]
Delcath inks European licensing deal for Chemosat
Delcath Systems (OTC:DCTH) said this week that it inked a licensing deal with Germany-based medac for the commercialization of Chemosat in Europe. According to the terms of the seven-year agreement, Delcath’s European subsidiary will exclusively license its Chemosat system to Medac for sale in the EU, Norway, Liechtenstein, Switzerland and the UK. Medac is slated to […]
Novocure backs $2m in brain cancer research grants
Novocure (NSDQ:NVCR) today, along with the American Association for Cancer Research, announced four inaugural Tumor Treating Fields research grants totaling more than $1.5 million. The St. Helier, Jersey-based company said that the newly launched grants include the AACR-Novocure Tumor Treating Fields Research Grant, the AACR-Novocure Career Development Award for Tumor Treating Fields Research, the AACR-Novocure Tumor Treating Fields Research Fellowship and […]
Novocure touts analysis of pivotal glioblastoma trial results
Novocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma. The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received […]
Boston Scientific offers $4B for BTG
Boston Scientific (NYSE:BSX) said today that it agreed to offer roughly $4.24 billion to acquire British medical device maker BTG (LON:BTG). The £8.40-per-share offer, worth about £3.3 billion, is a 36.6% premium over BTG’s closing price yesterday and a 51.0% premium over the stock’s 90-day volume-weighted average price, the London-based company said. BTG’s largest division makes devices for oncology […]
BTG invests $20m in Veran Medical’s thoracic guidance tech
BTG (LON:BTG) said this week that it invested $20 million in Veran Medical Technologies and its thoracic navigation system. Veran’s thoracic navigation system is designed to help lung specialists diagnose lung cancer earlier, enabling a smooth transition between an endobronchial and transthoracic approach. The technology is also used to localize and mark lung nodules in […]
- 1
- 2
- 3
- …
- 72
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube